3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Conditions
Urinary Bladder Neoplasms
2
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
490
Carboplatin
436
Gemcitabine
394
Docetaxel
385
Cisplatin
360
pembrolizumab
344
Bevacizumab
335
Nivolumab
261
Pemetrexed
243
Capecitabine
221
Dexamethasone
213
Fluorouracil
211
Rituximab
203
Trastuzumab
193
Cyclophosphamide
190
Oxaliplatin
160
Erlotinib Hydrochloride
147
Ipilimumab
145
atezolizumab
144
Prednisone
144
Cetuximab
142
Irinotecan
139
Leucovorin
130
Doxorubicin
130
Sorafenib
120
Lenalidomide
119
Bortezomib
118
Sunitinib
107
Everolimus
93
130-nm albumin-bound paclitaxel
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
INDUSTRY
×
Mycobacterium w vaccine
×
Clear all
NCT00694915
2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2
Completed
122 enrolled
NCT00680940
2012-08-07
NSCLC
Cadila Pharnmaceuticals
Phase 2
Completed
221 enrolled
NCT00694798
2012-05-03
STCC
Cadila Pharnmaceuticals
Phase 1
Completed
22 enrolled